
"Sector" = median of Healthcare across 84 companies
ResMed Inc. is a global leader in cloud-connected medical devices and digital health solutions for people with sleep apnea, chronic obstructive pulmonary disease (COPD), and other respiratory conditions. The company designs, manufactures, and distributes continuous positive airway pressure (CPAP) devices, masks, and related accessories, along with diagnostic and monitoring equipment. ResMed also offers a comprehensive software platform, AirView, that enables remote patient monitoring and data-driven care management.
ResMed generates revenue through two primary segments: Sleep and Respiratory Care (devices, masks, and accessories) and Software as a Service (SaaS) for out-of-hospital healthcare. The device business accounts for the majority of sales, with recurring revenue from consumables like masks and filters. The SaaS segment, bolstered by acquisitions such as Brightree and MatrixCare, provides cloud-based solutions for home medical equipment providers, hospices, and nursing homes, contributing stable subscription income.
The company operates in the medical instruments and supplies industry within the healthcare sector. ResMed is the dominant player in the sleep apnea market, with an estimated 70% share of the CPAP device market globally. Its main competitors include Philips Respironics (which faced a major recall in 2021), Fisher & Paykel Healthcare, and smaller players. ResMed’s competitive advantages include its strong brand, extensive patent portfolio, and integrated digital health ecosystem.
ResMed’s primary customers are patients with sleep-disordered breathing and respiratory conditions, as well as healthcare providers such as sleep clinics, hospitals, and home medical equipment dealers. The company sells through a mix of direct sales, distributors, and online channels. Geographically, the United States is the largest market, accounting for over 60% of revenue, followed by Europe, Asia Pacific, and other regions. The aging population and rising awareness of sleep apnea are key growth drivers.
An auto-generated descriptive profile based on company data, for informational purposes only.
No 24-hour summary has been generated yet.
Latest saved period: March 2026 · 2026-03-31
Cash dividends by ex-date, not an investment recommendation.
| Ex-date | Amount | Payment date | Period |
|---|---|---|---|
| Feb 12, 2026 | $0.60 | Mar 16, 2026 | Quarterly |
| Nov 13, 2025 | $0.60 | Dec 18, 2025 | Quarterly |
| Aug 14, 2025 | $0.60 | Sep 18, 2025 | Quarterly |
| May 8, 2025 | $0.53 | Jun 12, 2025 | Quarterly |
| Feb 13, 2025 | $0.53 | Mar 20, 2025 | Quarterly |
| Nov 7, 2024 | $0.53 | Dec 12, 2024 | Quarterly |
| Aug 15, 2024 | $0.53 | Sep 19, 2024 | Quarterly |
| May 8, 2024 | $0.48 | Jun 13, 2024 | Quarterly |
| Feb 7, 2024 | $0.48 | Mar 14, 2024 | Quarterly |
| Nov 8, 2023 | $0.48 | Dec 14, 2023 | Quarterly |
| Aug 16, 2023 | $0.48 | Sep 21, 2023 | Quarterly |
| May 10, 2023 | $0.44 | Jun 15, 2023 | Quarterly |
| Feb 8, 2023 | $0.44 | Mar 16, 2023 | Quarterly |
| Nov 9, 2022 | $0.44 | Dec 15, 2022 | Quarterly |
| Aug 17, 2022 | $0.44 | Sep 22, 2022 | Quarterly |
| May 11, 2022 | $0.42 | Jun 16, 2022 | Quarterly |
| Feb 9, 2022 | $0.42 | Mar 17, 2022 | Quarterly |
| Nov 9, 2021 | $0.42 | Dec 16, 2021 | Quarterly |
| Aug 18, 2021 | $0.42 | Sep 23, 2021 | Quarterly |
| May 12, 2021 | $0.39 | Jun 17, 2021 | Quarterly |
| Feb 10, 2021 | $0.39 | Mar 18, 2021 | Quarterly |
| Nov 10, 2020 | $0.39 | Dec 17, 2020 | Quarterly |
| Aug 19, 2020 | $0.39 | Sep 24, 2020 | Quarterly |
| May 13, 2020 | $0.39 | Jun 18, 2020 | Quarterly |
Wrqti brings ResMed Inc. data into one page covering available price, financial statements, valuation ratios, margins, cash-flow metrics, news, and alerts. This page helps you understand the numbers and is not a buy or sell recommendation.
Companies in the Healthcare sector you can compare with ResMed Inc.:
When available, the page shows quarterly and annual statements plus ratios such as PE, price to book, profit margin, and free cash flow. Latest financial period shown: March 2026.
Wrqti content depends on available data and third-party sources and may include delays or errors. Review official company filings and consult a licensed financial advisor before making investment decisions. Read the data methodology.